Most drugmakers did not share with ASHP a reason for the shortage, but one cited the supply issue as a reason for high demand. The shortage of the common flu drug is not national, according to the FDA, but some local pockets are noting increased demand and shortages.
Here’s how the oseltamivir shortage breaks down as of Jan. 11, per ASHP:
- Alembic Pharmaceuticals has one presentation on back order with a resupply date of late January and two others on allocation.
- Amneal Pharmaceuticals has four oseltamivir products on back order.
- Camber Pharmaceuticals has three on allocation.
- Lupin Limited has four on allocation.
- Macleods Pharma has one on back order with a release date of early February and another on allocation.
- Novadoz has three on allocation.
- Teva Pharmaceuticals has one on intermittent back order and is resupplying as product becomes available.
- Zydus Lifesciences has one on allocation.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.